Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psych Congress Network
Watch Dr. Jain discuss his seven tips to help to gauge what is working, what is not working, and where there is room for improvement in treating and managing your adult patients with ADHD.
Psychiatry July 5th 2022
MDLinx
The research shows that chronic pain, inflammatory bowel disease, cancer, and migraines all play a role in the development of mental diseases. Healthcare practitioners should take a careful history and keep in mind comorbidities when treating patients for any of these conditions.
Gastroenterology July 5th 2022
In this Q&A, Dr. Vincent Millischer describes the surprising association between lithium clearance and serum lithium as well as the role that genetics may play in helping to determine the proper lithium dosage for each patient.
ReachMD
In this 30-minute, 0.50 credit CME activity, participants will be better able to define treatment response, remission and treatment resistance in MDD; identify patients with inadequate response to antidepressants who may benefit from treatment modification; select an appropriate next-step treatment strategy for a patient with partial response to an antidepressant; and compare pharmacologic and adverse effect profiles of SGAs approved for adjunctive treatment of MDD.
JAMA Network
With fast symptom relief and reinforcing effects, benzodiazepines were once the gold standard for treating insomnia and anxiety. As opioids dominate headlines along with the public health crisis of drug overdose deaths, is it time to reconsider benzodiazepines as a course of treatment?
Psychiatry June 21st 2022
To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases due to challenges at the blood-brain barrier. James Bibb, Ph.D., and colleagues seek to change that notion with their brain-permeable compound, 25-106.
Neurology June 21st 2022